Literature DB >> 20651819

Peroxisome proliferator-activated receptor gamma promotes neuroprotection by modulating cyclin D1 expression after focal cerebral ischemia.

Lichun Pei1, Yanqiao Zhang, Yina Zhang, Xiaojie Chu, Jingyuan Zhang, Ruitao Wang, Meiling Liu, Xiuying Zhu, Weigang Yu.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) has been shown to protect against stroke and improve neurological outcome after cerebral ischemia. This study investigated whether activation of cerebral PPARgamma improves recovery from focal cerebral ischemia by reducing expression of cyclin D1, which is associated with programmed neuron death. Focal cerebral ischemia was induced by 90 min of middle cerebral artery occlusion (MCAO), followed by reperfusion. Intracerebroventricular (i.c.v.) infusion of the PPARgamma agonist ciglitazone, beginning 5 days before and continuing through 1 day after MCAO, reduced infarct size and cyclin D1 expression in the peri-infarct cortical region. Furthermore, primary cortical neurons treated with ciglitazone showed suppressed expression of cyclin D1 in response to hypoxia-reoxygenation. This protective effect was reversed after cotreatment with the selective PPAR-gamma antagonist GW 9662 (2-chloro-5-nitrobenzanilide), clearly demonstrating the involvement of a PPARgamma-dependent mechanism. Our data provide evidence that activation of neuronal PPARgamma makes a substantial contribution to neuroprotection by preventing cyclin D1 up-regulation in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20651819     DOI: 10.1139/y10-058

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  7 in total

1.  The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.

Authors:  M Carla Cabrera; Edgar S Díaz-Cruz; Bhaskar V S Kallakury; Michael J Pishvaian; Clinton J Grubbs; Donald D Muccio; Priscilla A Furth
Journal:  Cancer Prev Res (Phila)       Date:  2012-04-16

2.  Angiotensin II type 2 receptor stimulation with compound 21 improves neurological function after stroke in female rats: a pilot study.

Authors:  Wael Eldahshan; Tauheed Ishrat; Bindu Pillai; Mohammed A Sayed; Abdulrahman Alwhaibi; Abdelrahman Y Fouda; Adviye Ergul; Susan C Fagan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-01       Impact factor: 4.733

3.  Acute and chronic lithium treatment increases Wnt/β-catenin transcripts in cortical and hippocampal tissue at therapeutic concentrations in mice.

Authors:  Vanessa J De-Paula; Carla Cristine C Dos Santos; Maria Carolina A Luque; Taccyana M Ali; Jorge E Kalil; Orestes V Forlenza; Edecio Cunha-Neto
Journal:  Metab Brain Dis       Date:  2020-11-10       Impact factor: 3.584

4.  Method parameters' impact on mortality and variability in rat stroke experiments: a meta-analysis.

Authors:  Jakob O Ström; Edvin Ingberg; Annette Theodorsson; Elvar Theodorsson
Journal:  BMC Neurosci       Date:  2013-04-01       Impact factor: 3.288

Review 5.  PPAR agonists as therapeutics for CNS trauma and neurological diseases.

Authors:  Shweta Mandrekar-Colucci; Andrew Sauerbeck; Phillip G Popovich; Dana M McTigue
Journal:  ASN Neuro       Date:  2013-12-18       Impact factor: 4.146

6.  Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice.

Authors:  Valérie Boujon; Ria Uhlemann; Stephanie Wegner; Matthew B Wright; Ulrich Laufs; Matthias Endres; Golo Kronenberg; Karen Gertz
Journal:  J Mol Med (Berl)       Date:  2019-05-30       Impact factor: 4.599

7.  Knockdown of XIST up-regulates 263294miR-340-5p to relieve myocardial ischaemia-reperfusion injury via inhibiting cyclin D1.

Authors:  Qijun Bai; Yan Li; Kunpeng Song; Jie Huang; Li Qin
Journal:  ESC Heart Fail       Date:  2021-12-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.